Innocan Pharma's Exciting Private Placement Initiative
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the company's growth and operational flexibility.
Structure of the Offering
Each unit will include one common share in the capital of Innocan and one common share purchase warrant. The warrants grant holders the opportunity to acquire additional common shares at a price of C$0.28 for a four-year period starting from the issuance date. This structured approach offers investors potential upside while equipping Innocan with necessary funds.
Purpose of the Funds
The proceeds from this placement will be directed towards enhancing working capital and supporting general corporate purposes. Such allocations are crucial as Innocan continues to develop innovative solutions within the pharmaceutical landscape.
Regulatory Considerations
The securities issued to Canadian subscribers will experience a hold period lasting four months and one day post-issuance, aligning with Canadian securities regulations. This ensures compliance while offering investors a degree of security in their investments.
About Innocan Pharma
Innocan stands out in the pharmaceutical and wellness sectors through its cutting-edge products. The company has pioneered a CBD-loaded liposome drug delivery platform, providing accurate dosing and controlled release of synthetic CBD for effective pain management. Furthermore, through its 60% owned subsidiary, BI Sky Global Ltd., Innocan focuses on a diverse range of self-care and beauty products aimed at promoting healthier lifestyles.
Recent Developments and Future Plans
Innocan’s ongoing commitment to research and innovation has positioned it as a leader in its field. With the anticipated funding from this private placement, the company aims to expand its product line and enhance distribution strategies. This strategy not only serves existing customer demands but also opens new avenues for market penetration.
Contact Information
For more detailed inquiries, you can reach Iris Bincovich, the CEO, at +1-516-210-4025 or +972-54-3012842. Email inquiries can be directed to info@innocanpharma.com.
Frequently Asked Questions
What is the reason behind Innocan's private placement?
The private placement aims to raise capital for working capital needs and general corporate purposes, crucial for Innocan's growth.
What will investors receive in the private placement?
Investors will receive units comprising one common share and one warrant, which allows them to buy another share at a later time.
How long will the hold period for the securities last?
The hold period for the securities issued will last for four months and one day following their issuance.
What sectors does Innocan Pharma operate in?
Innocan operates in both the pharmaceuticals and wellness sectors, providing innovative solutions for pain management and self-care products.
How can I learn more about Innocan Pharma?
For more information, you can visit Innocan's official website or contact the CEO directly through the provided contact details.
